Curacle Co

Curacle Co Financial Leverage

The Financial Leverage (Equity Multiplier) of Curacle Co (365270.KQ) as of Nov 7, 2026 is 1.43. In the previous year, Financial Leverage (Equity Multiplier) was 1.98 — a change of -27.52% (lower).

Financial Leverage

1.43

YoY

-27.52%

Last updated:

Financial Leverage (Equity Multiplier) of Curacle Co is 2025 1.43 . Financial Leverage (Equity Multiplier) of Curacle Co was 2024 1.98 . It decreases by -27.52% lower compared to the previous year.

The Curacle Co Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
-6.28 KRW
Jan 1, 2019
-1.05 KRW
Jan 1, 2020
1.89 KRW
Jan 1, 2021
1.19 KRW
Jan 1, 2022
1.21 KRW
Jan 1, 2023
1.67 KRW
Jan 1, 2024
1.98 KRW
Jan 1, 2025
1.43 KRW
The Curacle Co Financial Leverage history
YEARFinancial LeverageYoY
1.43-27.52%
1.98+18.74%
1.67+38.28%
1.21+1.21%
1.19-36.85%
1.89-279.39%
-1.05-83.26%
-6.28—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Curacle Co Stock analysis

What does Curacle Co do? Curacle Co., Ltd. generates revenue through the research and development of synthetic drugs CU06-RE, CU01, and natural drug CU03, targeting intractable vascular diseases. These drugs address diabetic macular edema (DME), diabetic nephropathy (DN), and wet age-related macular degeneration (wet AMD). The company leverages its SOLVADYS platform technology, a specialized platform for developing vascular endothelial dysfunction blockers, to advance its drug development pipeline. The primary buyers of Curacle's products are pharmaceutical companies and medical institutions seeking innovative treatments for vascular-related conditions. The company focuses on intractable vascular diseases, a niche segment where current treatments are limited, positioning its drugs as novel solutions. SOLVADYS platform technology is utilized by the company internally to enhance its research capabilities and streamline drug development processes. Curacle's business model centers on developing proprietary drug candidates and platform technology, with revenue streams derived from potential future licensing agreements, partnerships, or direct sales of its drug candidates. The company's focus on rare and complex vascular diseases ensures a targeted market segment with high unmet medical needs, attracting interest from specialized healthcare providers and pharmaceutical developers. Curacle Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curacle Co stock

Financial Leverage (Equity Multiplier) of Curacle Co is 1.43 in 2025.

Financial Leverage (Equity Multiplier) of Curacle Co changed from 1.98 to 1.43, representing a -27.52% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Curacle Co since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Curacle Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Curacle Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Curacle Co